November 1, 2018
Authored and Edited by Shuo (Josh) Zhang; M. Andrew Holtman, Ph.D.
On October 15, 2018, FDA issued draft guidance on Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings. This draft guidance is intended to assist sponsors of drug and biological products for the treatment of rare diseases in early development and in the planning of and participation in formal pre-investigational new drug application (pre-IND) meetings with FDA. FDCA defines a rare disease as a disease or condition that affects fewer than 200,000 people in the United States. The guidance outlines regulatory, scientific, and other additional issues that FDA considers in being flexible to accommodate the unique challenges of rare disease drug development (such as limited number of available patients and lack of development precedent.)
In evaluating clinical evidence to establish safety and efficacy in the rare disease setting, the guidance reserves the broadest possible scientific judgment. FDA would consider: (1) benefits and risks of the drug; (2) seriousness of the disease; and (3) whether an unmet medical need exists. The guidance recognizes that patients and physicians are generally willing to accept greater risks and side effects from treatment of life-threatening and severely debilitating diseases.
The guidance flexibly evaluates nonclinical studies and sufficiency of data to assess whether clinical trials can be reasonably safe. An abbreviated or deferred program can be available in some cases. Animal models may contribute as well. Information related to clinical pharmacology also helps FDA in flexibly determining which clinical pharmacology studies are essential, whether those studies can be integrated with other clinical trials, and which studies can be deferred.
The guidance encourages sponsors to discuss with FDA on pediatric study plans, expedited programs for serious conditions, and orphan drug product incentives. Study plans for a companion diagnostic co-development are also recommended.
Readers are encouraged to read the draft guidance.
drugs, Food and Drug Administration (FDA), FDA Guidance, new drug application (NDA), Federal Food Drug and Cosmetic Act (FDCA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.